Exports are a measure of trust in the company's manufacturing capabilities. A good export track requires stringent quality control as well as strict adherence to patent laws and a respect for confidentiality of the client for process. High quality norms have helped get our products and capabilities certification from regulatory authorities such as USFDA and TGA, European certificate of suitability, MCA UK, Irish Board of Medicines, TGA and USFDA.

Exports are a thrust area now for NPIL and are expected to touch Rs 35 crores in 2002-2003 while the projected exports for 2003-2004 should reach Rs 100 crores. The growth plank for this has been the takeover of ICI which had a significant bulk drug export business.

GBDFC too has existing relationships with Pharma majors in the regulated markets in the Generics and the New Drug Delivery (NDD) segment. The company currently exports to the European and Canadian markets and also hopes to export to the US in the near future.